{
  "_id": "6c5167c765ef41527d5eab85d8e7d1eed66e53f98920a52864ba3622d0ce5d0a",
  "feed": "market-watch",
  "title": "Pharma giants take interest in acquiring Horizon Therapeutics",
  "text": "<p>Any tie-up, however, is uncertain and a deal may not emerge, the people said.</p><p>Horizon is Nasdaq-listed, but headquartered in Ireland and with operations in Dublin, Deerfield, Ill., and a new facility in Rockville, Md. It develops medicines to treat rare autoimmune and severe inflammatory diseases that are currently sold mostly in the U.S. Its biggest drug, Tepezza, is used to treat thyroid eye disease, an affliction characterized by progressive inflammation and damage to tissues around the eyes.</p><p>Last year, revenue from the product more than doubled, driving the company's overall net sales 47% higher to $3.23 billion. Horizon said this month that annual global net sales of the drug are targeted to eventually peak at more than $4 billion as the company aims to win approval to sell it in Europe and Japan.</p><p>An expanded version of this report appears on WSJ.com.</p><p>Also popular on WSJ.com:</p><p>Yield curve inversion reaches new extremes.</p><p>Elon Musk's Apple attack sets stage for public spat with risks for Apple, Twitter.</p><p>Pharma giants take interest in acquiring Horizon Therapeutics</p>",
  "published": "2022-11-29T21:45:00.000Z",
  "tags": [
    {
      "id": "US0378331005",
      "nexusId": "10022657",
      "name": "Apple Inc.",
      "offsets": [
        {
          "start": 950,
          "end": 955
        },
        {
          "start": 1005,
          "end": 1010
        }
      ]
    }
  ]
}